

Effectiveness of therapeutic heparin versus prophylactic heparin, mechanical ventilation, or intensive care unit admission in moderate to severe trauma patients admitted to hospital: RAPID randomised clinical trial

BMJ, The

375, n2400

DOI: [10.1136/bmj.n2400](https://doi.org/10.1136/bmj.n2400)

Citation Report

#	ARTICLE	IF	CITATIONS
1	PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19. <i>Viruses</i> , 2021, 13, 2128.	1.5	4
2	Host-modifying drugs against COVID-19: some successes, but not yet the breakthrough. <i>Environmental Microbiology</i> , 2021, 23, 7257-7270.	1.8	0
3	Impaired glucose regulation, SARS-CoV-2 infections and adverse COVID-19 outcomes. <i>Translational Research</i> , 2022, 241, 52-69.	2.2	8
4	Therapeutic-dose heparin should integrate the standard of care of moderately ill patients with COVID-19 admitted to hospital. <i>European Heart Journal</i> , 2022, 43, 365-366.	1.0	0
5	Anticoagulant therapy for COVID-19: What we have learned and what are the unanswered questions?. <i>European Journal of Internal Medicine</i> , 2022, 96, 13-16.	1.0	9
6	Therapeutic implications of ongoing alveolar viral replication in COVID-19. <i>Lancet Rheumatology</i> , The, 2022, 4, e135-e144.	2.2	17
7	Anticoagulant Treatment Regimens in Patients With Covid-19: A Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 614-623.	2.3	20
8	Interpreting recent clinical studies for COVID-19: A continual process with more new data. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2022, 41, 101016.	0.6	3
9	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. <i>Nature Reviews Cardiology</i> , 2022, 19, 475-495.	6.1	180
10	Efficacy and safety of therapeutic vs. prophylactic bempiparin in noncritically ill patients with COVID-19 pneumonia. <i>European Journal of Internal Medicine</i> , 2022, , .	1.0	3
11	Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy. <i>Vaccines</i> , 2022, 10, 192.	2.1	20
12	Anticoagulation in COVID-19. <i>Lancet</i> , The, 2022, 399, 5-7.	6.3	18
13	Platelets and Antiplatelet Medication in COVID-19-Related Thrombotic Complications. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 802566.	1.1	7
14	Upper extremity deep vein thrombosis in COVID-19: Incidence and correlated risk factors in a cohort of non-ICU patients. <i>PLoS ONE</i> , 2022, 17, e0262522.	1.1	8
15	Antiplatelet Therapy in Patients With COVID-19—More Is Less?. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 223.	3.8	10
16	Non-severe COVID-19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1008-1014.	1.9	18
17	Anticoagulation as a therapeutic strategy for hospitalised patients with COVID-19. <i>Thrombosis Update</i> , 2022, 6, 100097.	0.4	1
18	Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. <i>European Heart Journal</i> , 2022, 43, 1157-1172.	1.0	297

#	ARTICLE	IF	CITATIONS
19	COVID-19 Coagulopathy: From Pathogenesis to Treatment. <i>Acta Haematologica</i> , 2022, 145, 282-296.	0.7	19
20	Thromboprophylaxis in Patients With COVID-19. <i>Chest</i> , 2022, 162, 213-225.	0.4	58
21	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. <i>Arthritis and Rheumatology</i> , 2022, 74, .	2.9	146
22	The association between anticoagulation and adverse outcomes after a positive SARS-CoV-2 test among older outpatients: A population-based cohort study. <i>Thrombosis Research</i> , 2022, 211, 114-122.	0.8	5
23	Efficacy and safety of increased doses of anticoagulants in COVID-19 patients: a systematic review and meta-analysis. <i>Hirurg</i> , 2022, , 50-65.	0.0	1
24	COVID-19 and venous thromboembolism: A narrative review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12666.	1.0	16
26	Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study. <i>Antibiotics</i> , 2022, 11, 241.	1.5	4
28	The COVID Complex: A Review of Platelet Activation and Immune Complexes in COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 807934.	2.2	24
29	Anticoagulants for people hospitalised with COVID-19. <i>The Cochrane Library</i> , 2022, 2022, CD013739.	1.5	27
30	Full <i>versus</i> prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis. <i>Haematologica</i> , 2022, 107, 1933-1939.	1.7	5
31	COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No. <i>Chest</i> , 2022, 161, 1448-1451.	0.4	6
32	Impact of Thromboprophylaxis Intensity on Patients's Mortality Among Hospitalized Patients with COVID-19: A Propensity-Score Matched Study. <i>Clinical Epidemiology</i> , 2022, Volume 14, 361-368.	1.5	1
33	Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3577-3599.	1.1	7
34	Anticoagulation in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2022, 79, 917-928.	1.2	35
35	POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes. <i>Chest</i> , 2022, 161, 1446-1448.	0.4	8
36	Coreceptor functions of cell surface heparan sulfate proteoglycans. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 322, C896-C912.	2.1	20
37	Prophylactic anticoagulation with low molecular weight heparin in COVID-19: cohort studies in Denmark and Sweden. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1291.e1-1291.e5.	2.8	3
38	Efficacy of different anticoagulant doses for patients with COVID-19: a systematic review and network meta-analysis. <i>Infection</i> , 2022, 50, 1453-1463.	2.3	4

#	ARTICLE	IF	CITATIONS
39	Role of Acute Thrombosis in COVID-19. <i>Critical Care Clinics</i> , 2022, , .	1.0	3
40	Surfing Corona waves â€œ instead of breaking them: Rethinking the role of natural immunity in COVID-19 policy. <i>F1000Research</i> , 0, 11, 337.	0.8	0
41	Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis. <i>Frontiers in Microbiology</i> , 2022, 13, 860931.	1.5	15
42	D-Dimer Values and Venous Thromboembolism in Patients With COVID-19 in Japanâ€™â€™â€™. From the CLOT-COVID Study â€™. <i>Circulation Reports</i> , 2022, , .	0.4	4
44	Thromboprophylaxis in COVIDâ€™19: Weight and severity adjusted intensified dosing. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12683.	1.0	4
45	Thromboinflammation and Antithrombotics in COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1234.	3.8	9
46	Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study. <i>Viruses</i> , 2022, 14, 767.	1.5	4
47	The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study. <i>Journal of Cardiology</i> , 2022, 80, 285-291.	0.8	18
48	Effect of Antiplatelet Therapy on Survival and Organ Supportâ€™Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1247.	3.8	83
49	Influence of sex on development of thrombosis in patients with COVID-19: From the CLOT-COVID study. <i>Thrombosis Research</i> , 2022, 213, 173-178.	0.8	12
50	The Pathobiological Basis for Thrombotic Complications in COVID-19: a Review of the Literature. <i>Current Pathobiology Reports</i> , 2021, 9, 107-117.	1.6	6
51	Randomized trials of therapeutic heparin for COVIDâ€™19: A metaâ€™analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12638.	1.0	39
52	Fundamentals in Covid-19-Associated Thrombosis: Molecular and Cellular Aspects. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 785738.	1.1	20
53	Risk Factors for Venous Thromboembolism in Severe COVID-19: A Study-Level Meta-Analysis of 21 Studies. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12944.	1.2	19
54	Enoxaparin for thromboprophylaxis in hospitalized COVIDâ€™19 patients: The Xâ€™COVIDâ€™19 Randomized Trial. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13735.	1.7	31
55	Safety and Efficacy of Intermediate- and Therapeutic-Dose Anticoagulation for Hospitalised Patients with COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 57.	1.0	11
56	First do no harm. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12694.	1.0	2
57	Anticoagulation as secondary prevention of massive lung thromboses in hospitalized patients with COVID-19. <i>European Journal of Internal Medicine</i> , 2022, 100, 21-24.	1.0	7

#	ARTICLE	IF	CITATIONS
58	To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 062-072.	1.5	13
59	Use of Anticoagulants in COVID-19: A Review. <i>American Journal of Therapeutics</i> , 2022, 29, e425-e436.	0.5	4
60	Perspective: The Case for Acute Large Vessel Ischemic Stroke in COVID-19 Originating Within Thrombosed Pulmonary Venules. <i>Stroke</i> , 2022, 53, 2411-2419.	1.0	3
61	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. <i>Blood Advances</i> , 2022, 6, 4915-4923.	2.5	42
62	Anticoagulant Treatment in Severe ARDS COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 2695.	1.0	4
63	Assessment of Bleeding Risk in Hospitalized COVID-19 Patients: A Tertiary Hospital Experience during the Pandemic in a Predominant Minority Population” Bleeding Risk Factors in COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 2754.	1.0	2
64	COVID-19 associated rhabdomyolysis leading to major amputation in the absence of macrovascular thrombosis. <i>Annals of Vascular Surgery Brief Reports and Innovations</i> , 2022, 2, 100082.	0.1	2
66	Venous and arterial thrombosis in COVID-19: An updated narrative review. <i>Journal of Infection and Public Health</i> , 2022, 15, 689-702.	1.9	6
67	Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 197-210.	1.0	29
68	Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-19 HEP randomized clinical trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	18
69	COVID-19 associated coagulopathy and thrombosis in cancer. <i>Thrombosis Research</i> , 2022, 213, S72-S76.	0.8	1
70	The Role of Heparin in COVID-19: An Update after Two Years of Pandemics. <i>Journal of Clinical Medicine</i> , 2022, 11, 3099.	1.0	13
71	To escalate thromboprophylactic heparin intensity in COVID-19 or not? That is still the question. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12738.	1.0	2
72	Anticoagulation in hospitalized patients with COVID-19. <i>Blood</i> , 2022, 140, 809-814.	0.6	12
73	Thrombotic events in critically ill children with coronavirus disease 2019 or multisystem inflammatory syndrome in children. <i>Current Opinion in Pediatrics</i> , 2022, 34, 261-267.	1.0	4
75	COVID-19 and Thrombosis: Pathophysiological Mechanisms and Therapeutic Update. , 0, , .		1
76	Annals for Hospitalists Inpatient Notes - Venous Thromboembolism Prophylaxis in COVID-19: Making Sense of the Evidence. <i>Annals of Internal Medicine</i> , 2022, 175, HO2-HO3.	2.0	1
77	Full Characterization of Thrombotic Events in All Hospitalized COVID-19 Patients in a Spanish Tertiary Hospital during the First 18 Months of the Pandemic. <i>Journal of Clinical Medicine</i> , 2022, 11, 3443.	1.0	5

#	ARTICLE	IF	CITATIONS
78	Efficacy and Safety of Intensified Versus Standard Prophylactic Anticoagulation Therapy in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	4
79	COVID Coagulopathy and Thrombosis: A Systematic Review. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 78.	0.1	2
80	High-dose versus low-dose venous thromboprophylaxis in hospitalized patients with COVID-19: a systematic review and meta-analysis. <i>Internal and Emergency Medicine</i> , 2022, 17, 1817-1825.	1.0	8
81	Efficacy and safety of hyperbaric oxygen treatment to treat COVID-19 pneumonia: a living systematic review update. <i>Diving and Hyperbaric Medicine</i> , 2022, 52, 126-135.	0.2	2
83	ISTH guidelines for antithrombotic treatment in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2214-2225.	1.9	100
84	Thromboprophylaxis in people hospitalized with COVID-19: Assessing intermediate or standard doses in a retrospective cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	0
85	Association Between the Development of Thrombosis and Worsening of Disease Severity in Patients With Moderate COVID-19 on Admission From the CLOT-COVID Study. <i>Circulation Journal</i> , 2023, 87, 448-455.	0.7	3
86	Heparin Resistance in SARS-CoV-2 Infected Patients with Venous Thromboembolism. <i>Hospital Pharmacy</i> , 0, , 001857872211117.	0.4	1
87	Bleeding and thrombotic events in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study. <i>Intensive Care Medicine</i> , 2022, 48, 1039-1052.	3.9	33
88	Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations—State-of-the-Art. <i>Anticancer Research</i> , 2022, 42, 3261-3274.	0.5	5
89	Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2226-2236.	1.9	23
90	Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis. <i>BMJ, The</i> , 0, , e070022.	3.0	7
91	A Prospective Study Evaluating Cumulative Incidence and a Specific Prediction Rule in Pulmonary Embolism in COVID-19. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	8
92	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. <i>Journal of Hepatology</i> , 2022, 77, 1161-1197.	1.8	46
93	An Insight Into Pathophysiology, Epidemiology, and Management of Cardiovascular Complications of SARS-CoV-2 Infection, Post-acute COVID Syndrome, and COVID Vaccine. <i>Critical Pathways in Cardiology</i> , 2022, 21, 123-129.	0.2	3
94	Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS. <i>Journal of Intensive Care</i> , 2022, 10, .	1.3	2
95	Therapeutic Approaches to the Neurologic Manifestations of COVID-19. <i>Neurotherapeutics</i> , 2022, 19, 1435-1466.	2.1	22
96	Does high-dose thromboprophylaxis improve outcomes in COVID-19 patients? A meta-analysis of comparative studies. <i>TH Open</i> , 0, , .	0.7	1

#	ARTICLE	IF	CITATIONS
97	Coagulopathy in COVID-19 and anticoagulation clinical trials. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101377.	0.7	3
98	Effect of therapeutic versus prophylactic anticoagulation therapy on clinical outcomes in COVID-19 patients: a systematic review with an updated meta-analysis. <i>Thrombosis Journal</i> , 2022, 20, .	0.9	3
100	Coronavirus Disease 2019-Associated Coagulopathy. <i>Microorganisms</i> , 2022, 10, 1556.	1.6	8
101	Deep Learning-Based Time-to-Death Prediction Model for COVID-19 Patients Using Clinical Data and Chest Radiographs. <i>Journal of Digital Imaging</i> , 2023, 36, 178-188.	1.6	6
102	Low molecular weight heparin is associated with better outcomes than unfractionated heparin for thromboprophylaxis in hospitalized COVID-19 patients: a meta-analysis. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 0, , .	1.8	1
103	The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	5
104	Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2022, 7, 60-62.	0.5	0
105	Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 420-430.	1.0	17
106	A systematic review of biomarkers among hospitalized patients with COVID-19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables Scientific and Standardization Committee of the ISTH. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	3
107	Venous Thromboembolic Disease in COVID-19, Pathophysiology, Therapy and Prophylaxis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10372.	1.8	3
108	Occurrence of Thromboembolic Events and Mortality Among Hospitalized Coronavirus 2019 Patients: Large Observational Cohort Study of Electronic Health Records. <i>TH Open</i> , 2022, 06, e408-e420.	0.7	5
109	Anticoagulation in COVID-19 patients – An updated systematic review and meta-analysis. <i>Thrombosis Research</i> , 2022, 219, 40-48.	0.8	12
110	Use of anticoagulants in patients with COVID-19: a living systematic review and meta-analysis. <i>Jornal Brasileiro De Pneumologia</i> , 0, , e20220041.	0.4	3
111	Standardization of D-dimer reporting in the COVID-19 era. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	1
112	Evolution of Approaches to Therapeutic Prevention and Treatment of the New Coronavirus Infection. <i>Herald of the Russian Academy of Sciences</i> , 2022, 92, 430-436.	0.2	0
113	A novel anticoagulation treatment protocol using unfractionated heparin for coronavirus disease 2019 patients in Japan, 2022. <i>Global Health & Medicine</i> , 2022, 4, 233-236.	0.6	1
114	COVID-19 patients with acute pulmonary embolism have a higher mortality risk: systematic review and meta-analysis based on Italian cohorts. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 773-778.	0.6	4
115	Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	2

#	ARTICLE	IF	CITATIONS
116	Which are the optimal thromboprophylaxis strategies for hospitalized patients with COVID-19? current controversies. <i>Vascular</i> , 2024, 32, 220-225.	0.4	0
117	The Case for Therapeutic-Intensity Anticoagulation in Patients with COVID-19-Associated Moderate Illness. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 076-078.	1.5	4
118	Higher Dose Anticoagulation Cannot Prevent Disease Progression in COVID-19 Patients: A Systematic Review and Meta-Analysis. <i>Biomedicines</i> , 2022, 10, 2194.	1.4	0
119	Predictors of fatal neurological complications among admitted COVID-19 patients with their implication in outcome: A Case Control study. <i>PLoS ONE</i> , 2022, 17, e0274485.	1.1	1
120	COVID-19 Thrombotic Complications and Therapeutic Strategies. <i>Annual Review of Medicine</i> , 2023, 74, 15-30.	5.0	4
121	Knowledge Gaps for Prophylactic Use of Antithrombotic Agents in Patients with COVID-19: Insights into New SARS-CoV-2 Variants, Vaccination Status, and Emerging Oral Antivirals. <i>Thrombosis and Haemostasis</i> , 2023, 123, 186-191.	1.8	4
122	Current practices in pediatric hospital-acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	0
123	The Comparison of Therapeutic With Prophylactic Anticoagulation on Mortality, Risk of Bleeding, and Thromboembolism in Hospitalized Patients With COVID-19: A Systematic Review. <i>Cureus</i> , 2022, , .	0.2	1
124	â€œ <sc>ISTH</sc> guidelines for antithrombotic treatment in COVID-19â€ Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2710-2711.	1.9	3
125	From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?. <i>Biomedicines</i> , 2022, 10, 2620.	1.4	6
126	Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 1169-1177.	5.2	14
127	Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options. <i>Life</i> , 2022, 12, 1605.	1.1	12
128	Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 695-709.	2.8	105
129	â€œ <sc>ISTH</sc> guidelines for antithrombotic treatment in <sc>COVID</sc> â€ Comment from Huisman et al.. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2708-2709.	1.9	0
130	Surfing Corona waves â€ instead of breaking them: Rethinking the role of natural immunity in COVID-19 policy. <i>F1000Research</i> , 0, 11, 337.	0.8	0
131	COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 816-832.	1.5	12
132	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
133	Therapeutic advances in COVID-19. <i>Nature Reviews Nephrology</i> , 2023, 19, 38-52.	4.1	67

#	ARTICLE	IF	CITATIONS
134	Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials. <i>Journal of Clinical Medicine</i> , 2022, 11, 5997.	1.0	13
135	Evaluation of a fast and frugal clinical decision algorithm (â€˜pathwaysâ€™™) on clinical outcomes in hospitalised patients with COVID-19 treated with anticoagulants. <i>Journal of Evaluation in Clinical Practice</i> , 2023, 29, 3-12.	0.9	3
136	Therapeutic vs prophylactic anticoagulation in COVID-19 patients: a systematic review and meta-analysis of real-world studies. <i>Minerva Cardiology and Angiology</i> , 0, , .	0.4	1
137	Assessment of Healthcare Resource Utilization by Anticoagulant Heparinoid Dosage Level in Patients Hospitalized with COVID-19. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962211378.	0.7	0
138	Efficacy and safety of increased doses of anticoagulants in COVID-19 patients: A systematic review and meta-analysis. <i>Vascular Investigation and Therapy</i> , 2022, 5, 59.	0.3	1
140	Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients â€˜ A retrospective cohort study on 5392 patients from a tertiary centre. <i>International Journal of Cardiology</i> , 2023, 372, 144-149.	0.8	2
141	How to use and report data on D-dimer testing in the COVID-19 era?. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	0
142	The potential impact of nanomedicine on COVID-19-induced thrombosis. <i>Nature Nanotechnology</i> , 2023, 18, 11-22.	15.6	6
144	Real-World Management of Pharmacological Thromboprophylactic Strategies for COVID-19 Patients in Japan. <i>JACC Asia</i> , 2022, 2, 897-907.	0.5	4
146	Thrombosis questions from the inpatient wards. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 481-490.	0.9	1
147	Nasopharyngeal viral load at admission is not an independent predictor of thromboembolic complications in unvaccinated COVID-19 hospitalized patients.. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 55, 282-288.	1.0	1
148	Anticoagulation Strategies in Non-Critically Ill Patients with Covid-19. , 2023, 2, .		5
149	To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 506-514.	0.9	4
150	Post-discharge Thromboembolic Events in COVID-19 Patients: A Review on the Necessity for Prophylaxis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2023, 29, 107602962211484.	0.7	5
151	Risk Factors and Impact on Outcomes of Thrombosis in Patients with COVID-19 in Japan: From the CLOT-COVID Study. <i>Annals of Vascular Diseases</i> , 2023, , .	0.2	0
152	Outcomes associated with antiphospholipid antibodies in COVID-19: A prospective cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100041.	1.0	4
153	A Review of Coronavirus Disease 2019 in Pregnancy. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 050-065.	0.8	0
154	Efficacy and safety of two heparin regimens for prevention of venous thromboembolism in hospitalized patients with COVID-19: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2023, 18, 863-877.	1.0	2

#	ARTICLE	IF	CITATIONS
155	Antithrombotic therapy in COVID-19 patients. <i>Obstetrics, Gynecology and Reproduction</i> , 2023, 16, 718-731.	0.2	1
156	Potential of plant extracts in targeting SARS-CoV-2 main protease: an <i>in vitro</i> and <i>in silico</i> study. <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-10.	2.0	3
157	Enoxaparin Posology According to Prothrombotic Status and Bleeding Risk in Hospitalized Patients with SARS-CoV-2 Pneumonia. <i>Journal of Clinical Medicine</i> , 2023, 12, 928.	1.0	0
158	The Conundrum of Anticoagulation for Hospitalized Patients with Covid-19. , 2023, 2, .		0
159	COVID-19 and comedications in atrial fibrillation—a case—control study in Stockholm. <i>European Journal of Epidemiology</i> , 2023, 38, 301-311.	2.5	1
160	Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles. <i>JAMA Network Open</i> , 2023, 6, e2253301.	2.8	0
161	Thromboembolic Events in COVID-19. <i>Contemporary Cardiology</i> , 2022, , 201-216.	0.0	0
162	Thromboembolic events in hospitalised patients with COVID-19: ecological assessment with a scoping review. <i>BMJ Open</i> , 2023, 13, e066218.	0.8	3
163	Incidence of lower limb deep vein thrombosis in patients with COVID-19 pneumonia through different waves of SARS-CoV-2 pandemic: A multicenter prospective study. <i>PLoS ONE</i> , 2023, 18, e0280247.	1.1	1
164	The Effect of Heparin Full-Dose Anticoagulation on Survival of Hospitalized, Non-critically Ill COVID-19 Patients: A Meta-analysis of High Quality Studies. <i>Lung</i> , 2023, 201, 135-147.	1.4	7
165	The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	17
166	Thrombosis and Anticoagulation Strategies in Patients with COVID-19 Including Japanese Perspective. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, 30, 311-320.	0.9	0
167	Pharmacology of Heparin and Related Drugs: An Update. <i>Pharmacological Reviews</i> , 2023, 75, 328-379.	7.1	16
168	MICHELLE trial: Inching towards the holy grail of post-discharge anticoagulation in Covid-19!. <i>The National Medical Journal of India</i> , 0, 35, 290-292.	0.1	0
172	Hospital pharmacy response to the COVID-19 pandemic: experience from a regional referral center in the United Arab Emirates. <i>Journal of Pharmaceutical Policy and Practice</i> , 2023, 16, .	1.1	1
173	Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19. <i>Journal of the American College of Cardiology</i> , 2023, 81, 1747-1762.	1.2	24
174	Thrombosis and bleeding in patients with COVID-19 requiring extracorporeal membrane oxygenation: a systematic review and meta-analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100103.	1.0	4
175	Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19. <i>JAMA Network Open</i> , 2023, 6, e232338.	2.8	7

#	ARTICLE	IF	CITATIONS
176	The effect of anti-coagulation dosage on the outcome of hospitalized COVID-19 patients in Ethiopia: a multi-center retrospective cohort study. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	0
177	Rivaroxabana em Pacientes Ambulatoriais com COVID-19 Leve ou Moderada: Fundamenta�o e Desenho do Estudo CARE (CARE � Coalition COVID-19 Brazil VIII). <i>Arquivos Brasileiros De Cardiologia</i> , 2023, 120, .	0.3	1
178	Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 1066.	3.8	25
180	Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia. <i>JAMA Internal Medicine</i> , 2023, 183, 520.	2.6	11
181	An Evolving Understanding of the Basis and Management of Vascular Complications of COVID-19: Where Do We Go From Here?. <i>Canadian Journal of Cardiology</i> , 2023, 39, 865-874.	0.8	2
182	Acute pancreatitis in pregnancy: how was it determined whether it was caused by pregnancy or by COVID-19? A case report. <i>Annals of Medicine and Surgery</i> , 2023, 85, 1104-1107.	0.5	4
183	D-dimer testing: A narrative review. <i>Advances in Clinical Chemistry</i> , 2023, , 151-223.	1.8	1
185	Pathophysiology of COVID-19 pneumonia and respiratory treatment. <i>Minerva Anestesiologica</i> , 2023, 89, .	0.6	1
186	SARS-CoV-2 RBD and Its Variants Can Induce Platelet Activation and Clearance: Implications for Antibody Therapy and Vaccinations against COVID-19. <i>Research</i> , 2023, 6, .	2.8	3
187	Superior Mesenteric Artery Thrombosis and Intestinal Ischemia as a Consequence of COVID-19 Infection. <i>Cureus</i> , 2023, , .	0.2	0
188	Treatment options for patients with severe COVID-19. <i>Global Health & Medicine</i> , 2023, 5, 99-105.	0.6	1
195	Continuation of therapeutic dose heparin for critically ill patients with COVID-19. <i>Intensive Care Medicine</i> , 2023, 49, 873-875.	3.9	3
198	COVID-19 and Hematopoietic Stem Cell Transplantation. , 2023, , 177-192.		0
210	Endothelium dysfunction and thrombosis in COVID-19 with type 2 diabetes. <i>Endocrine</i> , 2023, 82, 15-27.	1.1	2
221	Reply to �Embracing imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19�. <i>Angiogenesis</i> , 2023, 26, 485-486.	3.7	0
239	COVID-19 und VTE-Prophylaxe. <i>Springer Reference Medizin</i> , 2024, , 1-11.	0.0	0